(Q56892112)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

meta-analysis

0 references

title

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

1 reference

1 reference

6

Giuseppe Viale

0 references

Aron Goldhirsch

8

object named as

Aron Goldhirsch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

4

Tommaso De Pas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Fabio Conforti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Laura Pala

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Vincenzo Bagnardi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Marco Martinetti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Richard D Gelber

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Giuseppe Viale

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

language of work or name

English

0 references

publication date

16 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

27 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

page(s)

737-746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

Sex differences in immune responses

27 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

SeXX Matters in Infectious Disease Pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

The Xs and Y of immune responses to viral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

A gender gap in autoimmunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Estrogen receptors regulate innate immune cells and signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Gender effect on in vitro lymphocyte subset levels of healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

1 reference

7 January 2021

Influence of Sex on Immunoglobulin Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

The X chromosome in immune functions: when a chromosome makes the difference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

SeXX matters in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Sex differences and hormonal effects on gut microbiota composition in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Sex disparities in cancer incidence by period and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Sex disparities in cancer mortality and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Gender Disparity and Mutation Burden in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Gender differences in drug responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Sex bias in trials and treatment must end.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

The influence of sex and gender on the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930261-4

7 January 2021

10.1016/S1470-2045(18)30261-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29778737%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference